ASCO 2015

Final Follow-up Results from RADIANT: Adjuvant Erlotinib Vs Placebo Following Complete Tumor Resection in Patients with Stage IB–IIIA EGFR-positive NSCLC

Conference Correspondent - ASCO 2015 - Lung Cancer

Tyrosine kinase inhibitors (TKIs) in advanced NSCLC increase progression-free survival (PFS), but in general do not change overall survival (OS).a In a randomized, double-blind phase 3 trial (RADIANT), the safety and efficacy of the tyrosine kinase inhibitor (TKI) erlotinib (E) [ Read More ]

Results from the REVEL Trial: Exposure-Response Relationship for Ramucirumab plus Docetaxel vs Docetaxel as Second-line Treatment of Metastatic NSCLC

Conference Correspondent - ASCO 2015 - Lung Cancer

Ramucirumab (RAM) is a recombinant, fully human anti-VEGFR-2 monoclonal antibody that has been FDA approved as second line therapy with docetaxel in patients with metastatic NSCLC who have experienced disease progression during or after platinum-based chemotherapy. An exploratory exposure-response analysis [ Read More ]

Docetaxel plus Ramucirumab vs Docetaxel plus Placebo as Second-line Treatment for Advanced NSCLC: a Phase 2 Multicenter Trial in Japan

Conference Correspondent - ASCO 2015 - Lung Cancer

Ramicirumab (RAM) is a human IgG1 monoclonal antibody that specifically binds to and inhibits vascular endothelial growth factor receptor-2 (VEGFR2).a A randomized global phase 3 trial (REVEL) demonstrated statistically significant improvement in overall survival (OS) and progression-free survival (PFS) for [ Read More ]

Results from the GENIUS Trial: Maintenance Therapy with Gefitinib/Pemetrexed vs Pemetrexed for Metastatic Lung Adenocarcinoma with No Sensitizing EGFR Mutation

Conference Correspondent - ASCO 2015 - Lung Cancer

Induction therapy with pemetrexed/platinum followed by maintenance with pemetrexed is a standard chemotherapy regimen in the frontline setting in patients with NSCLC harboring no sensitizing EGFR mutations. In this patient population, no survival benefit has been observed with gefitinib monotherapy [ Read More ]